Alterity Therapeutics (ATHE) Competitors $4.04 -0.01 (-0.12%) Closing price 07/3/2025 01:19 PM EasternExtended Trading$4.02 -0.02 (-0.47%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. ALEC, ACOG, INMB, ACTU, CGEN, FATE, KYTX, BDTX, VXRT, and LXEOShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Alector (ALEC), Alpha Cognition (ACOG), INmune Bio (INMB), Actuate Therapeutics (ACTU), Compugen (CGEN), Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), and Lexeo Therapeutics (LXEO). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Alector Alpha Cognition INmune Bio Actuate Therapeutics Compugen Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Alterity Therapeutics (NASDAQ:ATHE) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment. Do institutionals & insiders hold more shares of ATHE or ALEC? 2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 9.1% of Alector shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate ATHE or ALEC? Alterity Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 197.40%. Alector has a consensus target price of $4.00, suggesting a potential upside of 171.19%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Alterity Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has preferable valuation and earnings, ATHE or ALEC? Alterity Therapeutics has higher earnings, but lower revenue than Alector. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlterity TherapeuticsN/AN/A-$12.54MN/AN/AAlector$100.56M1.47-$119.05M-$1.26-1.17 Is ATHE or ALEC more profitable? Alterity Therapeutics has a net margin of 0.00% compared to Alector's net margin of -139.74%. Alterity Therapeutics' return on equity of 0.00% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Alterity TherapeuticsN/A N/A N/A Alector -139.74%-100.58%-25.15% Does the media favor ATHE or ALEC? In the previous week, Alector had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 1 mentions for Alector and 0 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 0.00 equaled Alector'saverage media sentiment score. Company Overall Sentiment Alterity Therapeutics Neutral Alector Neutral Which has more volatility and risk, ATHE or ALEC? Alterity Therapeutics has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, Alector has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500. SummaryAlterity Therapeutics beats Alector on 7 of the 12 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$36.80M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E RatioN/A21.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book3.887.538.035.65Net Income-$12.54M-$55.14M$3.18B$249.15M7 Day Performance2.67%4.61%2.93%3.28%1 Month Performance-14.69%0.90%1.72%3.95%1 Year Performance120.81%5.40%34.39%20.98% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.6344 of 5 stars$4.04-0.1%$12.00+197.4%+120.8%$36.80MN/A0.0010ALECAlector3.8331 of 5 stars$1.38-6.5%$4.00+190.9%-66.4%$146.99M$88.34M-1.09270ACOGAlpha Cognition1.6923 of 5 stars$9.00-1.7%$20.00+122.2%N/A$146.74MN/A-7.50N/ANews CoveragePositive NewsINMBINmune Bio1.5818 of 5 stars$6.22-2.5%$22.80+266.6%-66.7%$146.64M$50K-3.2210News CoverageAnalyst ForecastGap DownHigh Trading VolumeACTUActuate Therapeutics2.9948 of 5 stars$7.05-5.6%$20.50+190.8%N/A$146.56MN/A0.0010CGENCompugen1.5373 of 5 stars$1.63-0.6%$4.00+145.4%+14.1%$146.35M$27.59M-10.1970Positive NewsFATEFate Therapeutics4.2667 of 5 stars$1.14-4.2%$3.83+236.3%-63.9%$136.38M$13.63M-0.77550News CoverageAnalyst RevisionKYTXKyverna Therapeutics1.2706 of 5 stars$3.22+4.9%$18.50+474.5%-58.7%$132.68M$7.03M-0.9596Gap DownBDTXBlack Diamond Therapeutics3.1219 of 5 stars$2.27-2.6%$14.60+543.2%-42.3%$132.49MN/A37.8390Positive NewsAnalyst UpgradeVXRTVaxart2.2529 of 5 stars$0.56-3.4%$3.00+435.3%-34.4%$132.42M$28.70M-2.08120LXEOLexeo Therapeutics1.8859 of 5 stars$3.96+1.3%$16.60+319.2%-71.4%$129.80M$650K-1.2058 Related Companies and Tools Related Companies ALEC Competitors ACOG Competitors INMB Competitors ACTU Competitors CGEN Competitors FATE Competitors KYTX Competitors BDTX Competitors VXRT Competitors LXEO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTHIS IS IT. Your FINAL CHANCE. At midnight, our 82% OFF July 4th deal disappears FOREVER. The countdown ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHE Stock Alerts